Subacute Cutaneous Lupus Erythematosus Induced by Mitotane [PDF]
Ander Mayor-Ibarguren +4 more
openalex +1 more source
Background: Only a fraction of patients with cutaneous lupus erythematosus (CLE) will eventually progress toward systemic disease (SLE). Objective: To find inflammatory biomarkers which could predict the progression of cutaneous lupus erythematosus (CLE)
Barbara Hartung Lovato +6 more
doaj +1 more source
Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands [PDF]
Sarika Ramachandran +5 more
openalex +1 more source
Management of Alopecia and Onychomycosis in a Lupus Patient
The array of potential differential diagnoses of cutaneous lupus erythematosus (CLE) is extensive. Exclusion of infection is paramount, given the patient’s immunodeficient state.
Muzayyana Sakiinah +4 more
doaj +1 more source
Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus
Karolina Pełka +3 more
openalex +2 more sources
Apoptosis and Redistribution of the Ro Autoantigen in Balb/c Mouse Like in Subacute Cutaneous Lupus Erythematosus [PDF]
Rafael Herrera‐Esparza +6 more
openalex +1 more source
Pustular and crusted lesions in systemic lupus erythematosus: A case report
Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease with various manifestations in the skin and several other organs. Subacute cutaneous lupus erythematosus may present with annular and psoriasiform lesions.
Allam P. Reddy +2 more
doaj +1 more source
Subacute cutaneous lupus erythematosus after mRNA-based SARS-CoV-2 vaccination. [PDF]
Rimmer S, Ly L, Boh E.
europepmc +1 more source
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus [PDF]
Victoria P. Werth +8 more
openalex +1 more source

